(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...
Merck's antibody therapy for early stage lung cancer patients who have previously undergone surgery to have tumors removed reduced the risk of the disease progressing or the patient dying by 24%, ...
Researchers identified predictors of immunotherapy response in advanced bladder cancer, including tumor mutational burden and APOBEC mutational signature. The FDA-approved combination of Keytruda and ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback